이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Endo International 관리

관리 기준 확인 3/4

Endo International's CEO는 Blaise Coleman, Dec2016 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 $ 12.85M, 7.6% 로 구성됩니다. 7.6% 급여 및 92.4% 보너스(회사 주식 및 옵션 포함). 는 $ 253.23 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 253.23. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 7 년입니다.

주요 정보

Blaise Coleman

최고 경영자

US$12.8m

총 보상

CEO 급여 비율	7.6%
CEO 임기	7.4yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

CEO 보상 분석

Blaise Coleman 의 보수는 Endo International 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	n/a	n/a	-US$2b
Sep 30 2023	n/a	n/a	-US$252m
Jun 30 2023	n/a	n/a	-US$942m
Mar 31 2023	n/a	n/a	-US$3b
Dec 31 2022	US$13m	US$978k	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	-US$3b
Mar 31 2022	n/a	n/a	-US$681m
Dec 31 2021	US$29m	US$913k	-US$569m
Sep 30 2021	n/a	n/a	US$129m
Jun 30 2021	n/a	n/a	US$109m
Mar 31 2021	n/a	n/a	US$137m
Dec 31 2020	US$7m	US$829k	US$247m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$75m
Mar 31 2020	n/a	n/a	-US$190m
Dec 31 2019	US$4m	US$612k	-US$361m
Sep 30 2019	n/a	n/a	-US$418m
Jun 30 2019	n/a	n/a	-US$522m
Mar 31 2019	n/a	n/a	-US$477m
Dec 31 2018	US$3m	US$569k	-US$962m
Sep 30 2018	n/a	n/a	-US$968m
Jun 30 2018	n/a	n/a	-US$921m
Mar 31 2018	n/a	n/a	-US$2b
Dec 31 2017	US$4m	US$546k	-US$1b

보상 대 시장: Blaise 의 총 보상 ($USD 12.85M )은 US 시장( $USD 683.56K ).

보상과 수익: Blaise 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Blaise Coleman (49 yo)

7.4yrs

테뉴어

US$12,849,847

보상

Mr. Blaise A. Coleman serves as President, Chief Executive Officer and Director of Endo Inc. Mr. Blaise serves as President, Chief Executive Officer and Director at Endo International plc since March 06, 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
Blaise Coleman	President	7.4yrs	US$12.85m	0.18% $ 253.2
Matthew Maletta	Executive VP	9yrs	US$4.25m	0.15% $ 210.7
James Tursi	Executive Vice President of Global Research & Development	2.3yrs	US$6.36m	데이터 없음
Mark Bradley	Executive VP & CFO	4.2yrs	US$7.98m	데이터 없음
Frank Raciti	VP, Controller & Chief Accounting Officer	no data	데이터 없음	데이터 없음
Cheryl Stouch	Senior VP of Information Technology & Chief Information Officer	1.9yrs	데이터 없음	데이터 없음
Laure Park	Senior Vice President of Investor Relations & Corporate Affairs	5.8yrs	데이터 없음	데이터 없음
Susan Williamson	Senior VP & Chief Compliance Officer	6.1yrs	데이터 없음	데이터 없음
Tracy Basso	Chief Human Resources Officer	4.8yrs	데이터 없음	데이터 없음
Patrick Barry	Executive VP & President of Global Commercial Operations	7.4yrs	US$7.78m	데이터 없음
James Papp	Head of Endo Ventures Limited & Senior VP of Global Supply Chain	3.5yrs	데이터 없음	데이터 없음
Michael McGuinness	Global Head of Quality & Compliance	1.9yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: ENDP.Q 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Blaise Coleman	President	4.2yrs	US$12.85m	0.18% $ 253.2
Mark Barberio	Independent Chairman	4.3yrs	US$840.00k	0.016% $ 22.9
Michael Hyatt	Independent Director	10.3yrs	US$625.00k	0.15% $ 213.3
William Montague	Independent Director	10.3yrs	US$625.00k	0.042% $ 59.3
Shane Cooke	Independent Director	9.8yrs	US$505.00k	0.043% $ 60.0
Jennifer Chao	Independent Director	3.3yrs	US$480.00k	0.011% $ 14.9
Nancy Hutson	Independent Director	10.3yrs	US$505.00k	0.047% $ 65.8
Mary Smith	Independent Non-Executive Director	3.8yrs	US$480.00k	0.014% $ 19.7

7.0yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: ENDP.Q 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Endo International 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Endo International plc, Annual General Meeting, Sep 07, 2023

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Chairman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$150k worth of stock

Endo International plc Appoints Jennifer M. Chao as Director, Audit Committee and its Compliance Committee

Recent updates

Endo International plc to Report Q1, 2024 Results on May 30, 2024

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International sees 23% rise on 3x higher than normal volume

Endo outperforms defying bankruptcy fears and generic entry

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International cools off, giving back some of its 85% Tuesday gain

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

Endo: Stick A Fork In It

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Price target decreased to US$2.63

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Endo: About As Bad As It Gets

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Price target decreased to US$6.17

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Endo: A Win In California But Equity Value Still A Question

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to US$6.57

Endo International: Loses Vasostrict Trial

Investor sentiment deteriorated over the past week

Endo International: Hires Restructuring Advisor

Consensus forecasts updated

Endo International: All About Ongoing Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Investor sentiment deteriorated over the past week

Endo International: Bankruptcy Seems Like The Only Practical Option

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Endo International wins FDA approval for Micafungin new formulation

Chairman Paul Campanelli has left the company

Senior Independent Director Roger Kimmel has left the company

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

Chairman exercised options and sold US$1.4m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week

Price target raised to US$7.45

Full year 2020 earnings released: EPS US$1.08 (vs US$1.60 loss in FY 2019)